AI-accelerated drug discovery Leverage Lavo Life Sciences' AI-accelerated quantum chemistry platform to position procurement and collaboration opportunities with mid-size biotech firms seeking faster drug development timelines and higher success rates in lead optimization.

Crystal Console launch Capitalize on the recent Crystal Console release to propose enterprise licenses or pilot programs for crystallography data analysis, visualization, and calculation tools to CROs and pharma partners needing enhanced small molecule characterization.

Sustainability & efficiency Frame the solution as reducing experimental overhead and material waste through accurate in silico simulations, appealing to R&D efficiency goals and potential grant or sustainability funding aligned with AI-driven drug discovery.

Growth and funding signals With revenue in the low millions and recent funding activity, pursue opportunities with founders or advisory contacts for strategic partnerships, co-development deals, or early-access programs that can scale with growing customer use cases.

Tech stack alignment Highlight compatibility with AWS, Google Cloud, and enterprise tools (OneTrust, Google Workspace) to address security, data governance, and collaboration needs of potential pharma clients seeking compliant, scalable AI chemistry solutions.